SKIN FIBROSIS TREATMENT MARKET ANALYSIS

Skin Fibrosis Treatment Market, by Drug Type (Corticosteroids, Antifibrotic, Immunotherapy Drugs, Other(Immunosuppressant)), by Route of Administration (Oral, Parenteral, Other(Topical)), by Application (Localized forms of scleroderma, Eosinophilic fasciitis, Scleromyxedema (papular mucinosis), and Scleredema), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI5255
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Skin Fibrosis Treatment Market: Key Developments

In May 2022, Michigan Medicine, University of Michigan Hospital, carried out studies on epigenetic drugs, which has shown promising results in cancer treatment significantly in reducing scarring in the cells of patients with scleroderma. The studies revealed that drugs that inhibit Bromodomain-containing protein 4(BRD4) can be used to treat fibrosis in scleroderma. The tests carried out by the researchers for the BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mice models of skin fibrosis showed that treatment terminated scarring in both animals and in human-derived cells.